|
|
|
|
Rizatriptan is a novel 5-HT 1B/lD agonist which is rapidly absorbed after oral administration.The efficacy and tolerability of oral rizatriptan(5 mg and 10 mg)were examined in this multicenter,double-blind,outpatient study of 1473 migraineurs which featured randomized,placebo-controlled treatment of migraine recurrences.The most common drug-related adverse experiences were dizziness,somnolence,asthenia/fatigue,and nausea(the incidences of which were low and dose-related).There was no increase in the incidence of adverse experiences after use of up to three doses of rizatriptan within 24 hours.We conclude that both doses of rizatriptan are effective and well tolerated in the acute treatment of migraine and migraine recurrence with the 10 mg dose preferred as it is more effective with a faster onset of action. |
|